Navigation Links
Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
Date:2/26/2013

LA JOLLA, Calif., Feb. 26, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Cowen and Company 33rd Annual Healthcare Conference on Tuesday, March 5, 2013 at 8:40 am EST.  The conference is being held at the Boston Marriott Copley Place.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of each webcast will be archived on the Company's website for two weeks following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
2. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
3. Regulus to Present at Two Upcoming Investor Conferences
4. Regulus Appoints Mark G. Foletta to its Board of Directors
5. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
7. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
8. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
9. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
10. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
11. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... 1, 2017 The Thyroid Pharmacist, Dr. ... foremost authorities on the thyroid and thyroid conditions, as ... activism, has designed and launched a revolutionary new 9-part ... deeps into the realities of thyroid disease, dispelling the ... path to recovery.  Dr. Wentz, who graduated ...
(Date:3/1/2017)... , March 1, 2017 Bio-Techne Corporation has ... Diagnostics to release its first diagnostic tool for ... innovative parasitological system which contains the only non-toxic, ... system will be manufactured at Bio-Techne,s Diagnostic Division ... and leverages its state-of-art formulation, manufacturing, and packaging ...
(Date:3/1/2017)... 1, 2017  Integrated Modular Design (IMD), ... and implementation of pre-fabricated healthcare products like ... headwalls, seeks to lead the construction industry ... Fueled by their leading-edge pre-fabrication ... reducing construction timelines and project risk, and ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... ... pricing in the month of March for treatments aimed at tightening skin and ... use on Thermage skin tightening, with 30 percent off all Thermage face and ...
(Date:3/1/2017)... ... March 01, 2017 , ... “Cleansing Thoughts; Glimpses ... of those who hear His voice. “Cleansing Thoughts; Glimpses from My Personal Journal” ... who enjoys boating, gardening and crocheting baby items to donate to the Neonatal ...
(Date:3/1/2017)... , ... March 01, 2017 , ... “Our Pure Need of Obedience to the Law ... for His return. “Our Pure Need of Obedience to the Law of God” is the ... attend missionary school. He and his wife, Anika, and children have since dedicated their lives ...
(Date:2/28/2017)... (PRWEB) , ... March 01, 2017 , ... ... the acquisition of SmarterMe, a personal assistant for sales powered by an intelligent ... enterprises to work smarter. , SmarterMe is built grounds up keeping individual users ...
(Date:2/28/2017)... St. Louis, Missouri (PRWEB) , ... February 28, ... ... will gather to learn and share “Pathways to Success: 21st Century Solutions to ... in San Diego, Calif. , “Each year, the Intalere Executive Forum assembles ...
Breaking Medicine News(10 mins):